FREE Webinar
Wednesday, September 13, 2017
2:30 - 4:00 p.m. EDT
Register Now
In the absence of new diagnostic tests for Parkinson’s disease (PD), the diagnosis has long been one of exclusion, ruling out other causes of tremor, bradykinesia, and rigidity. With the dawn of biomarker-based molecular diagnostics, a new race has begun to identify molecular signatures of disease pathology in noninvasively derived tissue samples, including blood, urine, and saliva, as well as radiographic or magnetic scans. Scientists have begun to sort through the molecular traces associated with PD patients to find telltale signs of disease onset and progression. The Scientist is bringing together a panel of experts to share their experience with biomarker discovery and validation, as well as their predictions for this as-yet-untapped ...
